5-((Tert-butoxycarbonyl)amino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid → 5-amino-N-(5-((4S,5S)-4-amino-5-fluoroazepan-1-yl)-1-cyclopropyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide
Reaction equation
[NH2:1][C:2]1[CH:3]=[N:4][N:5]([CH:22]2[CH2:24][CH2:23]2)[C:6]=1[N:7]1[CH2:13][CH2:12][CH:11]([F:14])[CH:10]([NH:15]C(=O)C(F)(F)F)[CH2:9][CH2:8]1.C(OC([NH:32][C:33]1[S:37][C:36]([C:38]2[C:43]([F:44])=[CH:42][CH:41]=[CH:40][C:39]=2[F:45])=[N:35][C:34]=1[C:46](O)=[O:47])=O)(C)(C)C>>[NH2:32][C:33]1[S:37][C:36]([C:38]2[C:43]([F:44])=[CH:42][CH:41]=[CH:40][C:39]=2[F:45])=[N:35][C:34]=1[C:46]([NH:1][C:2]1[CH:3]=[N:4][N:5]([CH:22]2[CH2:23][CH2:24]2)[C:6]=1[N:7]1[CH2:13][CH2:12][C@H:11]([F:14])[C@@H:10]([NH2:15])[CH2:9][CH2:8]1)=[O:47]Participants
3
Reactant 2
Product 1
Procedure
Following the procedure for Example 107 starting from N-(1-(4-amino-1-cyclopropyl-1H-pyrazol-5-yl)-5-fluoroazepan-4-yl)-2,2,2-trifluoroacetamide and 5-(tert-butoxycarbonyl-amino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid gave, after purification via preparative HPLC, 278 as the monoformate salt as an off-white solid (209 mg, 50% over two steps). 1H NMR (400 MHz, d4-MeOD) δ 8.54 (s, 1H), 7.52 (s, 1H), 7.51-7.44 (m, 1H), 7.19-7.12 (m, 2H), 4.86 (dtd, J=48.0, 9.3, 3.0 Hz, 1H), 3.61-3.47 (m, 2H), 3.48-3.36 (m, 4H), 2.46-2.32 (m, 1H), 2.26-2.05 (m, 2H), 1.99-1.86 (m, 1H), 1.23-1.11 (m, 2H), 1.13-1.05 (m, 2H). LCMS (ES+) m/z 492 (M+1)
Workup
- customgave
- customafter purification via preparative HPLC, 278 as the monoformate salt as an off-white solid (209 mg, 50% over two steps)
Sources & evidence
- ORD record
- ord-31f127aeff004b57a463650f69904126
- Source dataset
- uspto-grants-2013_12
- Patent number
- US08614206B2
Reaction notes
Loading…